Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Disease activation and laboratory parameters in Fibromyalgia Syndrome: Relationship with C-reactive protein/albumin ratio, neutrophil/lymphocyte ratio, mean platelet volume

Melih Pamukcu, Rabia Aydogan Baykara, Tugba Izci Duran.




Abstract

Fibromyalgia syndrome (FMS) is a chronic, widespread painful disease with unexplained etiopathogenesis and somatic-psychic findings. Unlike inflammatory rheumatic diseases, there are no specific laboratory parameters in FMS. In our study, we aimed to investigate the relationship between inflammatory markers and FMS activation scales. Eighty patients aged 18-65 years, diagnosed with FSM according to the American College of Rheumatology (ACR) 1990 criteria, were evaluated retrospectively. 61 healthy controls matched for sex, age, and body mass index (BMI) constituted the control group. In addition to the demographic data of the patients, the fibromyalgia impact questionnaire (FIQ) score, visual analog scale (VAS) fatigue score, VAS pain score, number of tender points, C- reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin, and complete blood count values were evaluated and compared statistically. FIQ, VAS pain, and VAS fatigue score, number of tender points were significantly higher in the patient group (p

Key words: Fibromyalgia syndrome (FMS), C-reactive protein/albumin ratio (CAR), neutrophil lymphocyte ratio (NLR), mean platelet volume (MPV)






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.